CA2683610A1 - Suspension formulations of insulinotropic peptides and uses thereof - Google Patents

Suspension formulations of insulinotropic peptides and uses thereof

Info

Publication number
CA2683610A1
CA2683610A1 CA002683610A CA2683610A CA2683610A1 CA 2683610 A1 CA2683610 A1 CA 2683610A1 CA 002683610 A CA002683610 A CA 002683610A CA 2683610 A CA2683610 A CA 2683610A CA 2683610 A1 CA2683610 A1 CA 2683610A1
Authority
CA
Canada
Prior art keywords
formulation
suspension
insulinotropic peptide
peptide
vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002683610A
Other languages
French (fr)
Other versions
CA2683610C (en
Inventor
Thomas R. Alessi
Ryan D. Mercer
Catherine M. Rohloff
Bing Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Intarcia Therapeutics, Inc.
Thomas R. Alessi
Ryan D. Mercer
Catherine M. Rohloff
Bing Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics, Inc., Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang filed Critical Intarcia Therapeutics, Inc.
Publication of CA2683610A1 publication Critical patent/CA2683610A1/en
Application granted granted Critical
Publication of CA2683610C publication Critical patent/CA2683610C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C07K7/067—Hemoregulatory peptides based on sequence Glp-Glu-Asp-Cys-Lys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T29/00—Metal working
    • Y10T29/49—Method of mechanical manufacture
    • Y10T29/494—Fluidic or fluid actuated device making

Abstract

A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide- 1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non¬ aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.

Claims (20)

1. A suspension formulation comprising, a particle formulation comprising an insulinotropic peptide, a disaccharide, methionine, and a buffer; and a non-aqueous, single-phase suspension vehicle comprising one or more pyrrolidone polymer and one or more solvent selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof;
wherein the suspension vehicle exhibits viscous fluid characteristics, and the particle formulation is dispersed in the vehicle.
2. The formulation of claim 1, wherein the insulinotropic peptide is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analogue of GLP-1.
3. The formulation of claim 2, wherein the insulinotropic peptide is GLP(7-36)amide.
4. The formulation of claim 1, wherein the insulinotropic peptide is exenatide, a derivative of exenatide, or an analogue of exenatide.
5. The formulation of claim 4, wherein the insulinotropic peptide is synthetic exenatide peptide.
6. The formulation of any of claims 1-5, wherein the buffer is selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.
7. The formulation of claim 6, wherein the buffer is a citrate.
8. The formulation of any of claims 1-7, wherein the disaccharide is selected from the group consisting of lactose, sucrose, trehalose, cellobiose, and mixtures thereof.
9. The formulation of any of claims 1-8, wherein the particle formulation is a spray dried preparation of particles.
10. The formulation of any of claims 1-9, wherein the solvent is selected from the group consisting of lauryl lactate, benzyl benzoate, and mixtures thereof.
11. The formulation of claim 10, wherein the solvent consists essentially of benzyl benzoate.
12. The formulation of any of claims 1-11, wherein the polymer consists essentially of polyvinylpyrrolidone.
13. The formulation of any of claims 1-12, wherein the vehicle consists essentially of a pyrrolidone and benzyl benzoate.
14. The formulation of claim 13, wherein the vehicle is about 50% solvent and about 50% polymer.
15. The formulation of any of claims 1-14, wherein the suspension formulation has an overall moisture content of less than or equal to about 10 wt%.
16. An osmotic delivery device, comprising the suspension formulation of any of claims 1-15.
17. A method of treating type II diabetes in a subject in need of such treatment, comprising delivering the suspension formulation of any of claims 1-15 from an osmotic delivery device at a substantially uniform rate for a period of about one month to about a year.
18. The method of claim 17, wherein the insulinotropic peptide is GLP-1(7-36)amide and delivering the suspension formulation is at a substantially uniform rate of between about 100 µg/day and about 600 µg/day.
19. The method of claim 17, wherein the insulinotropic peptide is exenatide and delivering the suspension formulation is at a substantially uniform rate of between about 5 µg/day and about 160 µg/day.
20. A method of manufacturing an osmotic delivery device comprising, loading the suspension formulation of any of claims 1-15 into a reservoir of the osmotic delivery device.
CA2683610A 2007-04-23 2008-04-22 Suspension formulations of insulinotropic peptides and uses thereof Active CA2683610C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92600507P 2007-04-23 2007-04-23
US60/926,005 2007-04-23
US7220208P 2008-03-28 2008-03-28
US61/072,202 2008-03-28
PCT/US2008/005235 WO2008133908A2 (en) 2007-04-23 2008-04-22 Suspension formulations of insulinotropic peptides and uses thereof

Publications (2)

Publication Number Publication Date
CA2683610A1 true CA2683610A1 (en) 2008-11-06
CA2683610C CA2683610C (en) 2013-01-08

Family

ID=39651340

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2683610A Active CA2683610C (en) 2007-04-23 2008-04-22 Suspension formulations of insulinotropic peptides and uses thereof

Country Status (19)

Country Link
US (5) US8299025B2 (en)
EP (1) EP2157967B1 (en)
JP (7) JP5351884B2 (en)
KR (1) KR101208381B1 (en)
CN (3) CN101715340A (en)
AU (1) AU2008244523B2 (en)
CA (1) CA2683610C (en)
CY (1) CY1114178T1 (en)
DK (1) DK2157967T3 (en)
ES (1) ES2402172T3 (en)
HK (2) HK1200336A1 (en)
HR (1) HRP20130259T1 (en)
IL (5) IL201175A (en)
MX (1) MX2009011123A (en)
NZ (1) NZ580447A (en)
PL (1) PL2157967T3 (en)
PT (1) PT2157967E (en)
RU (1) RU2440097C2 (en)
WO (1) WO2008133908A2 (en)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280020B1 (en) 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
DK1786784T3 (en) 2004-08-20 2011-02-14 Mannkind Corp Catalysis of diketopiperazine synthesis
PL2322180T3 (en) 2004-08-23 2015-10-30 Mannkind Corp Diketopiperazine salts for drug delivery
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN104324366B (en) 2005-09-14 2016-10-05 曼金德公司 Method for preparation of drug based on improving the active agent affinity to crystalline microparticle surfaces
MX360812B (en) 2006-02-22 2018-11-16 Mannkind Corp A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent.
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
WO2008133908A2 (en) * 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US8785396B2 (en) * 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2229407B1 (en) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Novel insulin derivatives having an extremely delayed time-action profile
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DE202009018480U1 (en) 2008-06-13 2012-01-26 Mannkind Corp. Dry powder inhaler and drug delivery system
MX2010014240A (en) 2008-06-20 2011-03-25 Mankind Corp An interactive apparatus and method for real-time profiling of inhalation efforts.
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
SG10201703039SA (en) 2008-09-04 2017-05-30 Amylin Pharmaceuticals Llc Sustained release formulations using non-aqueous carriers
US20100092566A1 (en) * 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
AU2014268265B2 (en) * 2008-10-15 2016-11-03 Intarcia Therapeutics, Inc. Highly concentrated drug particles, formulations, suspensions and uses thereof
CR20170369A (en) 2008-10-17 2017-11-01 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST (Divisional 2011-0188)
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (en) 2009-06-12 2018-07-06 맨카인드 코포레이션 Diketopiperazine microparticles with defined specific surface areas
CA2980198C (en) * 2009-07-06 2019-04-30 Sanofi-Aventis Deutschland Gmbh Insulin preparations containing methionine
EP2461818B1 (en) 2009-08-03 2018-10-17 Incube Labs, Llc Swallowable capsule and method for stimulating incretin production within the intestinal tract
AU2014280920B2 (en) * 2009-09-28 2016-05-12 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011037623A1 (en) * 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
EP3345593B1 (en) * 2009-11-13 2023-09-06 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
EP3417871B1 (en) * 2009-11-13 2020-12-23 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
CN102274182B (en) * 2010-06-13 2013-04-03 上海现代药物制剂工程研究中心有限公司 Multivesicular liposome containing exenatide, preparation method and application thereof
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
KR101823320B1 (en) 2010-08-30 2018-01-31 사노피-아벤티스 도이칠란트 게엠베하 Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
JP2014502985A (en) * 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス GLP-1 particles and compositions
CN103298457A (en) * 2011-01-19 2013-09-11 诺沃—诺迪斯克有限公司 GLP-1 compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3225235B1 (en) * 2011-03-10 2020-12-16 Xeris Pharmaceuticals, Inc. Stable peptide formulations for parenteral injection
WO2012122535A2 (en) * 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
BR122020008875B8 (en) 2011-04-01 2022-12-06 Mannkind Corp BLISTER PACKAGING AND METHOD OF MANUFACTURING A BLISTER PACKAGE
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
PL2773331T3 (en) 2011-10-31 2016-08-31 Xeris Pharmaceuticals Inc Formulations for the treatment of diabetes
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
KR102264177B1 (en) 2012-07-12 2021-06-11 맨카인드 코포레이션 Dry powder drug delivery systems and methods
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
WO2014096149A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 Derivatives
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
BR112015023168B1 (en) 2013-03-15 2021-08-10 Mannkind Corporation COMPOSITION OF 3,6-BIS(N-FUMARYL-4-AMINOBUTYL)-2,5-CRYSTALLINE DICETOPIPERAZINE, METHOD OF PRODUCTION OF 3,6-BIS(N-FUMARYL-4-AMINOBUTYL)-2,5-DICETOPIPERAZINE PARTICLES AND USE OF A CRYSTALLINE DICETOPIPERAZINE COMPOSITION
CN114848614A (en) 2013-07-18 2022-08-05 曼金德公司 Heat stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6735674B2 (en) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ Stabilized pharmaceutical formulation of insulin aspart
JP6641280B2 (en) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ Stabilized pharmaceutical formulations of insulin analogues and / or insulin derivatives
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6982495B2 (en) 2014-08-06 2021-12-17 ゼリス ファーマシューティカルズ インコーポレイテッド Syringes, kits, and methods for intradermal and / or subcutaneous injection of paste
WO2016037128A1 (en) * 2014-09-04 2016-03-10 Nano Precision Medical, Inc. Polymeric stabilizing formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
ES2949095T3 (en) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
RS62368B1 (en) 2015-05-22 2021-10-29 Univ Leland Stanford Junior Treatment of post-bariatric hypoglycemia with exendin(9-39)
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
WO2016201248A1 (en) * 2015-06-10 2016-12-15 Xeris Pharmaceuticals, Inc. Use of low dose glucagon
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3528836A1 (en) 2016-10-20 2019-08-28 Peptron, Inc. Methods of delivering a neuroprotective polypeptide to the central nervous system
AU2017361539B2 (en) 2016-11-21 2023-06-29 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
JP7242060B2 (en) * 2017-04-10 2023-03-20 武漢格睿特科技有限公司 POLYPEPTIDE USED TO TREAT METABOLIC DISEASE AND COMPOSITION THEREOF
JP7299166B2 (en) 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド Precipitation-resistant small molecule drug formulation
KR20200044016A (en) 2017-08-24 2020-04-28 노보 노르디스크 에이/에스 GLP-1 composition and use
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US20210244658A1 (en) * 2018-08-24 2021-08-12 North Carolina State University Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery
WO2020127950A1 (en) 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
AU2020219125A1 (en) 2019-02-05 2021-08-12 Lindy Biosciences, Inc. Isolated cell culture components and methods for isolating the same from liquid cell culture medium
AU2020270985A1 (en) * 2019-04-11 2021-12-09 Pfizer Ireland Pharmaceuticals Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN110732020B (en) * 2019-11-25 2023-10-03 江苏豪森药业集团有限公司 Stable pharmaceutical formulation containing polyethylene glycol lozenges
JP7132441B2 (en) 2020-02-18 2022-09-06 ノヴォ ノルディスク アー／エス GLP-1 compositions and uses thereof
CN115493919B (en) * 2022-11-21 2023-04-07 保定佳瑞源生物芯片有限公司 Calibrator diluent of C peptide and insulin detection kit

Family Cites Families (665)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR640907A (en) 1927-06-25 1928-07-24 Automatic flow limiter
US2168437A (en) 1935-04-10 1939-08-08 Kenneth O Buercklin Injection device
US2110208A (en) 1937-02-12 1938-03-08 U S Standard Products Company Antigen preparations
US3025991A (en) 1960-05-23 1962-03-20 Carron Products Co Bottle stopper
NL280825A (en) 1962-07-11
GB1049104A (en) 1963-05-11 1966-11-23 Prodotti Antibiotici Spa Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3122162A (en) 1963-06-20 1964-02-25 Asa D Sands Flow control device
BE744162A (en) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd ENCAPSULATION PROCESS
US3632768A (en) 1969-10-02 1972-01-04 Upjohn Co Therapeutic composition and method for treating infections with actinospectacin
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (en) 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3732865A (en) 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
JPS523342B2 (en) 1972-01-26 1977-01-27
BE795516A (en) 1972-02-17 1973-08-16 Ciba Geigy PREPARATIONS OF OILY AND INJECTABLE PEPTIDES AND PROCESS FOR THEIR PREPARATION
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3995632A (en) 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
DE2528516A1 (en) 1974-07-05 1976-01-22 Sandoz Ag NEW GALENIC PREPARATION
JPS523653A (en) 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4203439A (en) 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
USD258837S (en) 1977-10-17 1981-04-07 Gambro Dialysatoren Gmbh And Co. Kg Dialyzer cartridge
US4243030A (en) 1978-08-18 1981-01-06 Massachusetts Institute Of Technology Implantable programmed microinfusion apparatus
US4305927A (en) 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
AU546785B2 (en) 1980-07-23 1985-09-19 Commonwealth Of Australia, The Open-loop controlled infusion of diabetics
US4350271A (en) 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4340054A (en) 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4455145A (en) 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
EP0080879B1 (en) 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4455143A (en) 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3220116A1 (en) 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach MICROBIOLOGICALLY MANUFACTURED (ALPHA) AND SS INTERFERONES, DNA SEQUENCES CODING FOR THESE INTERFERONES, MICROORGANISMS CONTAINING THIS GENETIC INFORMATION, AND METHOD FOR THE PRODUCTION THEREOF
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US4966843A (en) 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4552561A (en) 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
DE3320583A1 (en) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach NEW GALENIC PREPARATION FORMS OF ORAL ANTIDIABETICS AND METHOD FOR THE PRODUCTION THEREOF
JPS6058915A (en) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd Lipid microcapsule preparation containing medicament
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
MX9203641A (en) 1983-12-16 1992-07-01 Genentech Inc RECOMBINANT GAMMA INTERFERONS THAT HAVE IMPROVED STABILITY AND BIOTECHNOLOGICAL METHODS FOR THEIR OBTAINING.
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4851228A (en) 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US4927687A (en) 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90990C (en) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Recombinant DNA molecule, transformed host organism, and method for producing interferon
US4655462A (en) 1985-01-07 1987-04-07 Peter J. Balsells Canted coiled spring and seal
JPS61189230A (en) 1985-02-19 1986-08-22 Nippon Kayaku Co Ltd Etoposide preparation
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IE59361B1 (en) 1986-01-24 1994-02-09 Akzo Nv Pharmaceutical preparation for obtaining a highly viscous hydrogel or suspension
DE3607835A1 (en) 1986-03-10 1987-09-24 Boehringer Ingelheim Int HYBRID INTERFERONS, THEIR USE AS MEDICINAL PRODUCTS AND AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF ANTIBODIES AND THE USE THEREOF AND METHOD FOR THEIR PRODUCTION
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4737437A (en) 1986-03-27 1988-04-12 East Shore Chemical Co. Light sensitive diazo compound, composition and method of making the composition
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4755180A (en) 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
DE3636123A1 (en) 1986-10-23 1988-05-05 Rentschler Arzneimittel ORAL ADMINISTRATIVE PREPARATIONS CONTAINING SINGLE DOSE FROM 10 TO 240 MG DIHYDROPYRIDINE
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
DE3642096A1 (en) 1986-12-10 1988-06-16 Boehringer Ingelheim Int HORSE (GAMMA) INTERFERON
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
JPH0720866B2 (en) 1987-05-15 1995-03-08 三生製薬株式会社 Transdermal preparation containing eperisone or tolperisone or their salts
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5938654A (en) 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
ATE86484T1 (en) 1987-08-08 1993-03-15 Akzo Nv CONTRACEPTIVE IMPLANT.
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4886668A (en) 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
GB8723846D0 (en) 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4907788A (en) 1988-04-25 1990-03-13 Peter J. Balsells Dual concentric canted-coil spring apparatus
US4974821A (en) 1988-04-25 1990-12-04 Peter J. Balsells Canted-coil spring with major axis radial loading
US5079388A (en) 1989-12-01 1992-01-07 Peter J. Balsells Gasket for sealing electromagnetic waves
US4964204A (en) 1988-04-25 1990-10-23 Peter J. Balsells Method for making a garter-type axially-resilient coil spring
DE68909295T2 (en) 1988-04-25 1994-05-11 Peter J Balsells Self-contained ring-shaped coil spring with an external, rearward angle of inclination.
US5160122A (en) 1990-03-20 1992-11-03 Peter J. Balsells Coil spring with an elastomer having a hollow coil cross section
US4876781A (en) 1988-04-25 1989-10-31 Peter J. Balsells Method of making a garter-type axially resilient coiled spring
US5117066A (en) 1988-04-25 1992-05-26 Peter J. Balsells Retaining and locking electromagnetic gasket
US4915366A (en) 1988-04-25 1990-04-10 Peter J. Balsells Outside back angle canted coil spring
US4826144A (en) 1988-04-25 1989-05-02 Peter J. Balsells Inside back angle canted coil spring
US4961253A (en) 1988-04-25 1990-10-09 Peter J. Balsells Manufacturing method for canted-coil spring with turn angle and seal
US4934666A (en) 1988-04-25 1990-06-19 Peter J. Balsells Coiled spring electromagnetic shielding gasket
US5108078A (en) 1988-04-25 1992-04-28 Peter J. Balsells Canted-coil spring loaded while in a cavity
US5203849A (en) 1990-03-20 1993-04-20 Balsells Peter J Canted coil spring in length filled with an elastomer
US4830344A (en) 1988-04-25 1989-05-16 Peter J. Balsells Canted-coil spring with turn angle and seal
US4893795A (en) 1988-08-15 1990-01-16 Peter J. Balsells Radially loaded canted coiled spring with turn angle
US5072070A (en) 1989-12-01 1991-12-10 Peter J. Balsells Device for sealing electromagnetic waves
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
JP2827287B2 (en) 1988-07-05 1998-11-25 武田薬品工業株式会社 Sustained release microcapsules containing water-soluble drugs
JP2794022B2 (en) 1988-11-11 1998-09-03 三生製薬株式会社 Transdermal preparation containing bunazosin or its salts
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5728088A (en) 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US4969884A (en) 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5234424A (en) 1988-12-28 1993-08-10 Alza Corporation Osmotically driven syringe
US4976966A (en) 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5906816A (en) 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5219572A (en) 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
EP0432232B1 (en) 1989-05-01 1994-01-05 Alkermes Controlled Therapeutics, Inc. Process for producing small particles of biologically active molecules
EP0471036B2 (en) 1989-05-04 2004-06-23 Southern Research Institute Encapsulation process
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
EP0489843A4 (en) 1989-08-28 1992-08-12 Pharmaceutical Delivery Systems, Inc. Bioerodible polymers useful for the controlled release of therapeutic agents
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5290558A (en) 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
SE465950B (en) 1989-10-23 1991-11-25 Medinvent Sa Combination of an aggregate particle size, crystalline or freeze-dried drug with a pseudoplastic gel for preparation of an injectable preparation as well as a process for its preparation
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JPH0659302B2 (en) 1989-11-13 1994-08-10 ベクトン・ディッキンソン・フランス・ソシエテ・アノニム Bottle
JPH03236317A (en) 1989-12-06 1991-10-22 Sansei Seiyaku Kk Dopamine derivative-containing percutaneous
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
USD326718S (en) 1989-12-26 1992-06-02 Minnesota Mining And Manufacturing Co. Blood sensor cassette
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5223266A (en) 1990-01-24 1993-06-29 Alza Corporation Long-term delivery device with early startup
US5213809A (en) 1990-01-24 1993-05-25 Alza Corporation Delivery system comprising means for controlling internal pressure
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5122128A (en) 1990-03-15 1992-06-16 Alza Corporation Orifice insert for a ruminal bolus
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5290271A (en) 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
JPH0441153A (en) 1990-06-07 1992-02-12 Daikin Ind Ltd Cooling device for built-in motor
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5122377A (en) 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
IT1243390B (en) 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
US5161806A (en) 1990-12-17 1992-11-10 Peter J. Balsells Spring-loaded, hollow, elliptical ring seal
GB9027422D0 (en) 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
WO1992011843A1 (en) 1991-01-09 1992-07-23 Alza Corporation Bioerodible devices and compositions for diffusional release of agents
NL9100160A (en) 1991-01-30 1992-08-17 Texas Instruments Holland INJECTOR.
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5861166A (en) 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
EP0720478A1 (en) 1991-05-07 1996-07-10 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5113938A (en) 1991-05-07 1992-05-19 Clayton Charley H Whipstock
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
EP0520119A1 (en) 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate New oral diclofenac composition
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
HU222501B1 (en) 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation
DE4122217C2 (en) 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Process for the preparation of mechanically stable, well decomposing compressed products from small active substance-containing moldings
US5288214A (en) 1991-09-30 1994-02-22 Toshio Fukuda Micropump
YU87892A (en) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center INJECTIBLE LONG TERM RELEASE FORMULATIONS AND PROCEDURES FOR THEIR OBTAINING AND USE
DE69229881T2 (en) 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical DELAYED RELEASE TABLET
JPH07500264A (en) 1991-10-10 1995-01-12 アルザ・コーポレーション Osmotic drug delivery device with hydrophobic wall material
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
AU3136293A (en) 1991-11-15 1993-06-15 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
DE4137649C2 (en) 1991-11-15 1997-11-20 Gerhard Dingler Component
US5200195A (en) 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
WO1993017075A1 (en) 1992-02-28 1993-09-02 Collagen Corporation High concentration homogenized collagen compositions
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
WO1993019739A1 (en) 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
EP0633907A1 (en) 1992-03-30 1995-01-18 Alza Corporation Additives for bioerodible polymers to regulate degradation
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
FR2690622B1 (en) 1992-04-29 1995-01-20 Chronotec Programmable ambulatory infusion pump system.
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
JP2651320B2 (en) 1992-07-16 1997-09-10 田辺製薬株式会社 Method for producing sustained-release microsphere preparation
US5413672A (en) 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
GB9223146D0 (en) 1992-11-05 1992-12-16 Scherer Corp R P Vented capsule
DE69224386T2 (en) 1992-11-06 1998-06-18 Texas Instruments Inc Device for subcutaneous insertion of a needle
EP0669128B1 (en) 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
SE9203594D0 (en) 1992-11-30 1992-11-30 Christer Nystroem DISPERSA SYSTEM MEDICINAL PRODUCT
PT674506E (en) 1992-12-02 2001-01-31 Alkermes Inc MICROSPHERES CONTAINING GROWTH HORMONE WITH CONTROLLED LIBERATION
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DK0686045T3 (en) 1993-02-23 2001-03-05 Genentech Inc Stabilization of organic solvent-treated polypeptides with an adjuvant
US5368588A (en) 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
AU6410494A (en) 1993-03-17 1994-10-11 Alza Corporation Device for the transdermal administration of alprazolam
US5514110A (en) 1993-03-22 1996-05-07 Teh; Eutiquio L. Automatic flow control device
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5639477A (en) 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
DE69401945T3 (en) 1993-06-25 2004-09-02 Alza Corp., Palo Alto INTRODUCTION OF A POLY-N-VINYLAMID INTO A TRANSDERMAL SYSTEM
US5498255A (en) 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
JP2700141B2 (en) 1993-09-17 1998-01-19 富士化学工業株式会社 Calcium hydrogen phosphate, its production method and excipient using the same
JP3792252B2 (en) 1993-09-29 2006-07-05 アルザ・コーポレーション Monoglyceride / lactate ester permeation enhancer for oxybutynin
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
JP3645906B2 (en) 1993-11-19 2005-05-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
ATE212830T1 (en) 1993-11-19 2002-02-15 Alkermes Inc PRODUCTION OF BIODEGRADABLE MICROPARTICLES CONTAINING A BIOLOGICALLY ACTIVE SUBSTANCE
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
JPH07196479A (en) 1994-01-04 1995-08-01 Unitika Ltd Method for producing microcapsule
USD358644S (en) 1994-01-18 1995-05-23 Bio Medic Data Systems, Inc. Transponder implanter
US6241734B1 (en) 1998-08-14 2001-06-05 Kyphon, Inc. Systems and methods for placing materials into bone
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
ATE224704T1 (en) 1994-02-04 2002-10-15 Lipocore Holding Ab DOUBLE-LAYER COMPOSITIONS OF GALACTOLIPIDE CONTAINING DIGALACTOSYLDIACYLGLYCEROL
US5697975A (en) 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
WO1995024212A1 (en) 1994-03-07 1995-09-14 Imperial College Of Science, Technology & Medicine The use of interferon subtypes in the preparation of medicaments to treat viral infections
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
DK0768867T3 (en) 1994-06-13 2002-10-28 Alza Corp Dosage form for administration of drug in liquid formulation
NL9401150A (en) 1994-07-12 1996-02-01 Nederland Ptt Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver.
JP4090072B2 (en) 1994-07-13 2008-05-28 アルザ・コーポレーション Compositions and methods for facilitating transdermal electrotransport agent administration
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
WO1996014834A1 (en) 1994-11-10 1996-05-23 University Of Kentucky Research Foundation Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
FR2731150B1 (en) 1995-03-03 1997-04-18 Oreal USE OF AMPHIPHILIC COMPOUNDS AS A THICKENING AGENT FOR NON-AQUEOUS MEDIA
US6100346A (en) 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US5700583A (en) 1995-03-06 1997-12-23 Ethicon, Inc. Hydrogels of absorbable polyoxaesters containing amines or amido groups
US6403655B1 (en) 1995-03-06 2002-06-11 Ethicon, Inc. Method of preventing adhesions with absorbable polyoxaesters
US5464929A (en) 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5844017A (en) 1995-03-06 1998-12-01 Ethicon, Inc. Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5859150A (en) 1995-03-06 1999-01-12 Ethicon, Inc. Prepolymers of absorbable polyoxaesters
US5595751A (en) 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5648088A (en) 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5962023A (en) 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US6147168A (en) 1995-03-06 2000-11-14 Ethicon, Inc. Copolymers of absorbable polyoxaesters
US5618552A (en) 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5542682A (en) 1995-03-27 1996-08-06 American Variseal Slant coil spring and seal
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
KR100404293B1 (en) 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 Composition for Oral Administration
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5718922A (en) 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
DK0831826T3 (en) 1995-06-06 2003-02-03 Hoffmann La Roche A pharmaceutical composition comprising a protease inhibitor and a monoglyceride
US5690952A (en) 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US6572879B1 (en) 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5876746A (en) 1995-06-07 1999-03-02 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5782396A (en) 1995-08-28 1998-07-21 United States Surgical Corporation Surgical stapler
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
GB9521125D0 (en) 1995-10-16 1995-12-20 Unilever Plc Cosmetic composition
SE505146C2 (en) 1995-10-19 1997-06-30 Biogram Ab Particles for delayed release
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
GB9521805D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Solubilisation methods
PT771817E (en) 1995-10-30 2003-06-30 Oleoyl Estrone Developments S OLEATE ESTERS OF ESTROGEN FOR THE TREATMENT OF OBESITY AND / OR EXCESS OF WEIGHT
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
PT858343E (en) 1995-11-02 2004-07-30 Schering Corp THERAPY FOR CONTINUOUS INFUSE OF A LOW DOSE OF CYTOKINE
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AUPN723395A0 (en) 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
EP0787569B1 (en) 1996-01-31 2002-10-02 Sumitomo Bakelite Company Limited Method of producing epoxy resin-encapsulated semiconductor device
DE69734168T2 (en) 1996-02-02 2006-01-19 Alza Corp., Mountain View Implantable system with delayed release of active ingredient
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
CA2279349C (en) 1996-02-02 2007-09-25 Rhomed Incorporated Ascorbate-stabilized radiopharmaceutical method and composition
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
ES2187756T3 (en) 1996-03-01 2003-06-16 Novo Nordisk As USE OF A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN APPETIZER SUPPRESSING PEPTIDE.
JPH09241153A (en) 1996-03-04 1997-09-16 Q P Corp Lipid emulsion for intravenous injection
CN1084747C (en) 1996-03-08 2002-05-15 曾尼卡有限公司 Azolobenzazepine derivs. as neurologically active agents
AU728146B2 (en) 1996-03-14 2001-01-04 Immune Response Corporation, The Targeted delivery of genes encoding interferon
US5703200A (en) 1996-03-15 1997-12-30 Ethicon, Inc. Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
WO1997035563A2 (en) 1996-03-28 1997-10-02 Takeda Chemical Industries, Ltd. Sustained-release preparation and its production
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6074673A (en) 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
DE69725745D1 (en) 1996-06-05 2003-11-27 Ashmont Holdings Ltd INJECTABLE COMPOSITIONS
JP2000516912A (en) 1996-06-05 2000-12-19 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Exendin analogs, methods for their preparation and formulations containing them
DE29610419U1 (en) 1996-06-14 1996-10-24 Filtertek Sa Gravity infusion device for medical infusions
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
PT909175E (en) 1996-07-03 2003-10-31 Alza Corp NON-AQUEOUS FORMULATIONS OF PROTIC PEPTIDES
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
ATE322272T1 (en) 1996-07-15 2006-04-15 Alza Corp NEW FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FLUOXETINE
AR008789A1 (en) 1996-07-31 2000-02-23 Bayer Corp PIRIDINES AND SUBSTITUTED BIPHENYLS
US6458337B1 (en) 1996-08-02 2002-10-01 Dibra S.P.A Diagnostic imaging contrast agent with improved in serum relaxivity
AU4063697A (en) 1996-08-08 1998-02-25 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
AU3981097A (en) 1996-08-21 1998-03-06 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5984890A (en) 1996-09-27 1999-11-16 American Home Products Corporation Medical device for the placement of solid materials
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
CA2264687C (en) 1996-10-24 2006-04-25 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US5817129A (en) 1996-10-31 1998-10-06 Ethicon, Inc. Process and apparatus for coating surgical sutures
UA65549C2 (en) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
DE19646392A1 (en) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Preparation for use in the oral cavity with a layer containing pressure-sensitive adhesive, pharmaceuticals or cosmetics for dosed delivery
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
PT1066081E (en) 1996-11-15 2003-12-31 Alza Corp OSMOTIC DISTRIBUTION SYSTEM AND PROCESS FOR IMPROVING THE START AND PERFORMANCE OF OSMOTIC DISTRIBUTION SYSTEMS
GB9626513D0 (en) 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
ATE203157T1 (en) 1996-12-20 2001-08-15 Alza Corp INJECTABLE DEPOSIT GEL PREPARATION AND PRODUCTION METHOD
CA2277112C (en) 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
JP2001511128A (en) 1997-01-28 2001-08-07 ファルマシア・アンド・アップジョン・カンパニー Lyophilized product of lipid complex of water-insoluble porphyrin
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
US5874388A (en) 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US6127520A (en) 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
JP2001524958A (en) 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ A novel liquid crystal based bioadhesive drug delivery system
TW577759B (en) 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
WO1998049321A2 (en) 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
MY125870A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JPH11100353A (en) 1997-09-29 1999-04-13 Esupo Kk Refined and deodorized liquid ester wax and its composition
DK1019022T4 (en) 1997-09-29 2010-11-08 Novartis Ag Perforated microparticles and their method of use
US6133429A (en) 1997-10-03 2000-10-17 Becton Dickinson And Company Chromophores useful for the preparation of novel tandem conjugates
WO1999025728A1 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU761577C (en) 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
US6368612B1 (en) 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells
CA2315890C (en) 1997-12-22 2009-08-11 Alza Corporation Rate controlling membranes for controlled drug delivery devices
KR100546982B1 (en) 1997-12-29 2006-01-26 알자 코포레이션 Implanter device for subcutaneous implants
JP4173635B2 (en) 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド Permeation supply apparatus having membrane plug holding mechanism
EP1300173B1 (en) 1997-12-29 2006-06-14 Alza Corporation Implanter device for subcutaneous implants
EP1041974B1 (en) * 1997-12-30 2006-10-11 Alza Corporation Beneficial agent delivery system with membrane plug
US20040024068A1 (en) 1998-01-23 2004-02-05 Trustees Of Tufts College Antimicrobial compounds
IT1298575B1 (en) 1998-02-06 2000-01-12 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
ATE366115T1 (en) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
USD408917S (en) 1998-02-26 1999-04-27 Minnesota Mining And Manufacturing Company Membrane support structure of a flow through cell for blood gas measurement
US6224577B1 (en) 1998-03-02 2001-05-01 Medrad, Inc. Syringes and plungers for use therein
US6056718A (en) 1998-03-04 2000-05-02 Minimed Inc. Medication infusion set
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US20020136848A1 (en) 1998-03-12 2002-09-26 Fumio Yoshii Lactone-containing resin composition, molded object thereof, and film
US6029361A (en) 1998-03-25 2000-02-29 Ultratech Stepper, Inc. Air-guage nozzle probe structure for microlithographic image focusing
US6074660A (en) 1998-04-20 2000-06-13 Ethicon, Inc. Absorbable polyoxaesters containing amines and/ or amido groups
TW586944B (en) 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
US8626302B2 (en) 1998-06-03 2014-01-07 Spr Therapeutics, Llc Systems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
SK19042000A3 (en) 1998-06-12 2001-11-06 Bionebraska, Inc. Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance
ATE428371T1 (en) 1998-07-17 2009-05-15 Pacira Pharmaceuticals Inc BIODEGRADABLE ARRANGEMENTS FOR THE CONTROLLED RELEASE OF ENCLOSED SUBSTANCES
US7390637B2 (en) 1998-07-21 2008-06-24 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
EP1112060B1 (en) 1998-09-09 2005-12-07 ALZA Corporation Dosage form comprising liquid formulation
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6248112B1 (en) 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
AU1238500A (en) 1998-11-02 2000-05-22 Alza Corporation Controlled delivery of active agents
WO2000029206A1 (en) 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ295890B6 (en) 1998-12-07 2005-11-16 Societe De Conseils De Recherches Et D'application GLP-1 analogues having aminoisobutyric acid in position 8 and D-arginine in position 36, their use and pharmaceutical compositions in which the analogues are comprised
ES2213404T3 (en) 1998-12-17 2004-08-16 Alza Corporation TRANSFORMATION OF GELATINE CAPSULES FILLED WITH LIQUID IN CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS.
KR100491815B1 (en) 1998-12-23 2005-05-27 암젠 인코포레이티드 Pharmaceutical composition comprising polyol/oil suspensions for the sustained release of proteins and process for preparing thereof
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
EP1140144A4 (en) 1998-12-31 2002-10-30 Viragen Inc Composition of highly purified natural mixtures of type i interferon derived from leukocytes and methods
AU771132B2 (en) 1998-12-31 2004-03-11 Intarcia Therapeutics, Inc. Osmotic delivery system having space efficient piston
WO2000040273A2 (en) 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
EP1143989B1 (en) 1999-01-14 2006-12-13 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
PT1140145E (en) 1999-01-14 2005-11-30 Amylin Pharmaceuticals Inc NEW FORMULATIONS OF EXENDINA AGONISTS AND METHODS FOR ITS ADMINISTRATION
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
EP1666026B2 (en) * 1999-02-08 2015-02-25 Intarcia Therapeutics, Inc Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2002043800A2 (en) 2000-11-29 2002-06-06 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
CA2367131C (en) 1999-04-05 2007-07-03 Solomon S. Steiner Methods for fine powder formation
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
CO5241354A1 (en) 1999-04-19 2003-01-31 Schering Corp HCV COMBINATION THERAPY
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
TR200103188T2 (en) 1999-05-07 2002-04-22 Pharmasol Gmbh Lipid particles based on liquid and solid lipid mixtures.
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP4115671B2 (en) 1999-05-17 2008-07-09 コンジュケム バイオテクノロジーズ インコーポレイテッド Long-lasting insulinotropic peptides
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
AU779277B2 (en) 1999-06-04 2005-01-13 Alza Corporation Implantable gel compositions and method of manufacture
US20010040326A1 (en) 1999-06-14 2001-11-15 Lord Corporation Resilient member with deformed element and method of forming same
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
SE9903236D0 (en) 1999-09-10 1999-09-10 Astra Ab Method of obtaining microparticles
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001043528A2 (en) 1999-12-17 2001-06-21 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
AU773354B2 (en) 1999-12-21 2004-05-20 Intarcia Therapeutics, Inc. Valve for osmotic devices
US6498193B2 (en) 1999-12-22 2002-12-24 Trustees Of Dartmouth College Treatment for complications of type 2 diabetes
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6472060B1 (en) 2000-01-19 2002-10-29 Seco Tools Ab Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
WO2001068112A2 (en) 2000-03-14 2001-09-20 Goeke Burkhard Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20030211974A1 (en) 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US8574146B2 (en) 2000-04-14 2013-11-05 Attenuex Technologies, Inc. Implant with high vapor pressure medium
ATE309822T1 (en) 2000-04-19 2005-12-15 Genentech Inc SUSTAINED RELEASE FORMULATIONS CONTAINING GROWTH HORMONE
WO2001080897A2 (en) 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
DE60134403D1 (en) 2000-05-19 2008-07-24 Amylin Pharmaceuticals Inc TREATMENT OF ACUTE CORONARY SYNDROME WITH GLP-1
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
DE60124710T2 (en) 2000-06-16 2007-09-13 Eli Lilly And Co., Indianapolis ANALOG OF GLUCAGON SIMILAR PEPTIDE-1
US6479065B2 (en) 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
AU2001296770A1 (en) 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
BR0115392A (en) 2000-11-03 2004-06-15 Biomedicines Inc Method for the treatment of an interferon-sensitive disease in a warm-blooded animal, method for individualizing the dosages of an interferon in treatment, method for manufacturing a long-term therapeutic effect delivery device of a drug over a period of time, and useful set for delivering a relatively constant amount of a drug
CA2429898C (en) 2000-11-16 2011-02-22 Durect Corporation Devices and methods for cholesterol management
DE60139430D1 (en) 2000-12-07 2009-09-10 Lilly Co Eli GLP-1 fusion proteins
US20020165286A1 (en) 2000-12-08 2002-11-07 Hanne Hedeman Dermal anti-inflammatory composition
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
CN1568195B (en) 2000-12-14 2011-03-02 安米林药品公司 Peptide YY and peptide YY agonists for treatment of metabolic disorders
US6899898B2 (en) 2000-12-21 2005-05-31 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
IN188924B (en) 2001-03-01 2002-11-23 Bharat Serums & Vaccines Ltd
EP1379197A4 (en) 2001-03-23 2009-06-03 Durect Corp Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
WO2002098348A2 (en) 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
US6514517B2 (en) 2001-06-20 2003-02-04 Ethicon, Inc. Antimicrobial coatings for medical devices
JP4460892B2 (en) 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド Sustained release composition
AU2002322289A1 (en) 2001-06-22 2003-01-08 Johns Hopkins University School Of Medicine Biodegradable polymer coompositions
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
AU2002304387A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
KR20040019069A (en) 2001-07-20 2004-03-04 인터뮨, 인크. Methods of treating liver fibrosis
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
HUP0501192A3 (en) 2001-08-23 2006-06-28 Lilly Co Eli Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003024357A2 (en) 2001-09-14 2003-03-27 Martin Francis J Microfabricated nanopore device for sustained release of therapeutic agent
US20050101942A1 (en) 2001-09-17 2005-05-12 Gillis Edward M. Device and method for accurate delivery of an active agent
BR0212985A (en) 2001-09-24 2005-08-30 Imp College Innovations Ltd Use of pyy or an agonist in the preparation of medicaments for treating disorders associated with overweight
JP2005508943A (en) 2001-10-05 2005-04-07 インターミューン インコーポレイテッド Treatment of hepatitis virus infection with multiphase interferon delivery profile
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
CA2460676C (en) 2001-10-24 2010-03-23 Claude Jolly Implantable fluid delivery apparatuses and implantable electrode
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
EP1536839B1 (en) 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
DE60239556D1 (en) 2001-11-14 2011-05-05 Durect Corp CATHETERINJICIBLE DEPOT COMPOSITIONS AND THEIR USE
BR0206984A (en) 2001-11-14 2004-02-03 Alza Corp Injectable Depot Compositions and Use of These
CN100446809C (en) 2001-11-14 2008-12-31 阿尔扎有限公司 Injectable depot composition
IL162099A0 (en) 2001-11-21 2005-11-20 Alza Corp Osmotic delivery device having a two-way valve anddynamically self-adjusting flow channel
DE10159217A1 (en) 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
US20030108608A1 (en) 2001-12-12 2003-06-12 Erik Laridon Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
HUP0402661A3 (en) 2001-12-19 2008-04-28 Alza Corp Formulation and dosage form for the controlled delivery of therapeutic agents
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
NZ535008A (en) 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
JP2005524657A (en) 2002-02-27 2005-08-18 ファーメイン， エルティーディー． Compositions for delivering therapeutic agents and other substances, and methods of making and using said compositions
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
GB2386066A (en) 2002-02-28 2003-09-10 Norbrook Lab Ltd Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
GB0204722D0 (en) 2002-02-28 2002-04-17 Norferm Da Method
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
JP4668611B2 (en) 2002-05-31 2011-04-13 タイタン ファーマシューティカルズ インコーポレイテッド Implantable polymer device for sustained release of buprenorphine
MXPA04012976A (en) 2002-06-17 2005-05-16 Alza Corp Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
BR0312429A (en) 2002-06-26 2005-04-19 Alza Corp Minimal and volume efficient deformity piston for osmosis drug delivery systems
US7177526B2 (en) 2002-06-28 2007-02-13 Intel Corporation System and method for improving audio during post-production of video recordings
CA2494342A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
DK1539101T3 (en) 2002-07-31 2009-04-27 Alza Corp Injectable, multi-modal polymeric compositions and applications thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040229814A1 (en) * 2002-08-28 2004-11-18 James Dillon Methods and compositions for protecting against cataract development associated with vitrectomies
WO2004022140A1 (en) 2002-09-04 2004-03-18 Ruark Botha Device for securing a blood vessel cannula to a body
US20040121009A1 (en) 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US7164005B2 (en) 2002-10-17 2007-01-16 Alkermes, Inc. Microencapsulation and sustained release of biologically active polypeptides
AU2003283004A1 (en) 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
ATE418323T1 (en) 2002-11-06 2009-01-15 Alza Corp DEPOSIT DELAYED RELEASE FORMULATIONS
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
JP2006512370A (en) 2002-12-19 2006-04-13 アルザ・コーポレーション A stable non-aqueous single phase gel and its formulation for delivery from an implantable device
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2004238392A (en) 2003-01-14 2004-08-26 Nipro Corp Stabilized proteinic preparation
US7507114B2 (en) 2003-02-18 2009-03-24 Medconx, Inc. Male medical device electrical connector with engineered friction fit
BRPI0408921A (en) 2003-03-31 2006-03-28 Alza Corp osmotic distribution system and method for decreasing start times for osmotic distribution systems
KR20060017749A (en) 2003-03-31 2006-02-27 알자 코포레이션 Osmotic pump with means for dissipating internal pressure
CN1767815A (en) 2003-03-31 2006-05-03 阿尔萨公司 Non-aqueous single phase vehicles and formulations utilizing such vehicles
DE202004009060U1 (en) 2003-05-16 2004-08-12 Blue Membranes Gmbh Biocompatible coated medical implants
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
ES2425221T3 (en) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc New methods and compositions for enhanced transmucosal delivery of peptides and proteins
CA2527664A1 (en) 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
EP2292254A3 (en) 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US8491571B2 (en) 2003-06-12 2013-07-23 Cordis Corporation Orifice device having multiple channels with varying flow rates for drug delivery
US7454765B2 (en) 2003-07-09 2008-11-18 Samsung Electronics Co., Ltd. Optical disc drive
JP2007501811A (en) * 2003-08-08 2007-02-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Use of galactose oxidase for selective chemical conjugation of a retarder molecule to a protein of therapeutic interest.
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7098243B2 (en) * 2003-09-16 2006-08-29 Kemin Pharma Europe B.V.B.A. Bicyclic carbohydrates as antiviral bioactives for the treatment of infections caused by the alphaherpesvirinae HSV-1 and HSV-2
US9005244B2 (en) 2003-09-30 2015-04-14 Ethicon, Inc. Tissue approximation device
BRPI0414941A (en) 2003-09-30 2006-11-07 Alza Corp osmotically driven active agent dispensing device providing an upward release profile
BRPI0416094A (en) 2003-10-31 2007-01-02 Alza Corp self-retaining quick start membrane plug osmotic pump
AU2004289218A1 (en) 2003-11-06 2005-05-26 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US7780973B2 (en) 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050216087A1 (en) 2004-01-05 2005-09-29 St. Francis Medical Technologies, Inc. Disk repair structures for positioning disk repair material
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
KR101040415B1 (en) 2004-04-15 2011-06-09 알케르메스,인코포레이티드 Polymer-based sustained release device
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
NZ553149A (en) * 2004-08-12 2010-01-29 Quest Pharmaceutical Services Use of inositol hexaphosphate or inositol hexasulphate to complex biologically active compounds for the preparation of controlled release pharmaceutical compositions
JP5244388B2 (en) 2004-08-18 2013-07-24 ウオーターズ・テクノロジーズ・コーポレイシヨン Apparatus and method for generating or carrying fluid under pressure and seal member used in the apparatus
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CA2584806C (en) 2004-11-01 2014-06-17 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US7575579B2 (en) 2004-11-18 2009-08-18 Union Surgical, Llc Drill guide tissue protector
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1841448A2 (en) * 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
AU2006207447B2 (en) 2005-01-24 2012-07-19 Merck Sharp & Dohme B.V. Applicator for inserting an implant
AU2006208131A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
JP2008528698A (en) * 2005-02-03 2008-07-31 インターシア セラピューティクス，インコーポレイティド Implantable interferon-containing devices
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2008530130A (en) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド GIP analogs and hybrid polypeptides with selectable properties
AU2006215566A1 (en) * 2005-02-16 2006-08-24 Novo Nordisk A/S Insulinotropic agents conjugated with structurally well defined branched polymers
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
ES2330671T3 (en) 2005-03-31 2009-12-14 Amylin Pharmaceuticals, Inc. AMILINA AND AMILINA AGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES AND DISORDERS.
ATE509634T1 (en) 2005-04-08 2011-06-15 Amylin Pharmaceuticals Inc PHARMACEUTICAL FORMULATIONS CONTAINING INCRETIN PEPTIDE AND APROTIC-POLAR SOLVENT
WO2006111169A1 (en) * 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US9233203B2 (en) 2005-05-06 2016-01-12 Medtronic Minimed, Inc. Medical needles for damping motion
DK1888031T3 (en) * 2005-06-06 2013-02-18 Camurus Ab GLP-1 analog formulations
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
GB2442396B (en) 2005-07-22 2011-05-11 Univ Utah Res Found Osmotically driven dispense pump and related components for use in high pressure applications
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
FI3524261T3 (en) 2005-08-19 2024-01-11 Amylin Pharmaceuticals Llc Exendin for use in treating diabetes and reducing body weight
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
HUE029798T2 (en) 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods for administering hypoglycemic agents
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329836A1 (en) 2005-12-16 2007-07-05 Amylin Pharmaceuticals, Llc Compositions and methods for treating obesity and related metabolic disorders
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
RU2427383C2 (en) * 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи High stability pharmaceutical compositions
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
EP3255149A3 (en) 2006-05-02 2018-04-18 Intrexon Actobiotics NV Microbial intestinal delivery of obesity related peptides
EP2029160A2 (en) 2006-05-12 2009-03-04 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
RU2456018C2 (en) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Prolonged-release pharmaceutical compositions for peptide delivery
WO2008019147A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
ES2422864T3 (en) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Osmotic release systems and piston units
JP2010505819A (en) 2006-10-05 2010-02-25 パナセア バイオテック リミテッド Depot type injection composition and preparation method thereof
WO2008061355A1 (en) * 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
US8262667B1 (en) 2007-02-23 2012-09-11 Holmed Corporation Multi-diameter implant forceps
WO2008133908A2 (en) * 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008134425A1 (en) 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
JP5718058B2 (en) 2008-02-08 2015-05-13 キューピーエス リミテッド ライアビリティ カンパニー Composition for slow broadcast of protein or peptide
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
US9186502B2 (en) 2008-02-14 2015-11-17 Enteromedics Inc. Treatment of excess weight by neural downregulation in combination with compositions
EP2259791A2 (en) 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
US20090234392A1 (en) 2008-03-13 2009-09-17 Depuy Spine, Inc. Method for inserting a spinal fixation element using implants having guide tabs
US8377881B2 (en) 2008-04-01 2013-02-19 MosaMedix B. V. Compositions and methods for reducing scar formation in wound healing
AU2009231601B2 (en) 2008-04-04 2014-02-27 Reshape Lifesciences, Inc. Methods and systems for glucose regulation
ES2552646T3 (en) 2008-05-21 2015-12-01 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
KR101683314B1 (en) 2008-09-17 2016-12-06 키아스마 인코포레이티드 Pharmaceutical compositions and related methods of delivery
RU2510266C2 (en) 2008-09-30 2014-03-27 Эндо Фармасьютикалз Солюшнз Инк. Implanted risperidone delivery system and methods for using it
US20100092566A1 (en) 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100298840A1 (en) 2009-05-22 2010-11-25 Schwartz Lyman D Phimosis Treatment Device and Method
US9358064B2 (en) 2009-08-07 2016-06-07 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Oxyntomodulin peptide analogue ‎
US8263554B2 (en) 2010-06-09 2012-09-11 Amylin Pharmaceuticals, Inc. Methods of using GLP-1 receptor agonists to treat pancreatitis
USD669589S1 (en) 2010-08-31 2012-10-23 Koninklijke Philips Electronics N.V. Blood system cartridge
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
US20130098928A1 (en) 2011-09-16 2013-04-25 Golden Aluminum, Inc. Application of designs to portion of food container
WO2013156628A1 (en) 2012-04-19 2013-10-24 Removaid As Device for removing an item implanted underneath the skin
WO2013180126A1 (en) 2012-05-29 2013-12-05 国立大学法人高知大学 Artery visualization device and artery imaging device
US20140058425A1 (en) 2012-08-27 2014-02-27 Amir Porat Manually operated surgical devices with operative portions formed of a see-through material
US9332995B2 (en) 2012-09-25 2016-05-10 Russo Inventions, Llc Bone-harvesting tool
EP2919764A1 (en) 2012-11-19 2015-09-23 Braeburn Pharmaceuticals BVBA SPRL Implantable drug delivery compositions and methods of treatment thereof
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system

Also Published As

Publication number Publication date
IL290847A (en) 2022-04-01
US9682127B2 (en) 2017-06-20
JP6016733B2 (en) 2016-10-26
IL201175A0 (en) 2010-05-17
US10363287B2 (en) 2019-07-30
MX2009011123A (en) 2009-11-02
US20150258016A1 (en) 2015-09-17
KR101208381B1 (en) 2012-12-05
JP6802019B2 (en) 2020-12-16
JP2019048815A (en) 2019-03-28
IL250929B (en) 2021-05-31
IL235813A (en) 2017-03-30
CA2683610C (en) 2013-01-08
US20170072022A1 (en) 2017-03-16
JP2021178848A (en) 2021-11-18
US20170368145A1 (en) 2017-12-28
CY1114178T1 (en) 2016-08-31
IL280217B (en) 2022-04-01
JP2014040420A (en) 2014-03-06
IL201175A (en) 2014-11-30
WO2008133908A3 (en) 2009-02-19
HRP20130259T1 (en) 2013-04-30
WO2008133908A2 (en) 2008-11-06
PT2157967E (en) 2013-04-03
JP2020094055A (en) 2020-06-18
US8940316B2 (en) 2015-01-27
DK2157967T3 (en) 2013-04-08
AU2008244523B2 (en) 2012-02-16
CN105688191A (en) 2016-06-22
EP2157967B1 (en) 2013-01-16
JP5351884B2 (en) 2013-11-27
CN104000779A (en) 2014-08-27
KR20090122386A (en) 2009-11-27
AU2008244523A1 (en) 2008-11-06
US20080260840A1 (en) 2008-10-23
JP2023166021A (en) 2023-11-17
HK1225966A1 (en) 2017-09-22
RU2009143016A (en) 2011-05-27
ES2402172T3 (en) 2013-04-29
CN101715340A (en) 2010-05-26
IL250929A0 (en) 2017-04-30
IL280217A (en) 2021-03-01
US20120178687A1 (en) 2012-07-12
RU2440097C2 (en) 2012-01-20
US8299025B2 (en) 2012-10-30
NZ580447A (en) 2011-06-30
PL2157967T3 (en) 2013-06-28
JP2017048193A (en) 2017-03-09
JP2010526775A (en) 2010-08-05
HK1200336A1 (en) 2015-08-07
EP2157967A2 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
CA2683610A1 (en) Suspension formulations of insulinotropic peptides and uses thereof
CA2602249A1 (en) Peptide and protein formulations with improved stability
Bose et al. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model
US10154957B2 (en) Microneedle device having a peptide therapeutic agent and an amino acid and methods of making and using the same
KR101243648B1 (en) Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Chae et al. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics
AU2012225268B2 (en) Stable formulations for parenteral injection of peptide drugs
CN101180081B (en) Stable polypeptide formulations
US20170007675A1 (en) Stable peptide formulations and methods for preparation
WO2005117967A3 (en) Anti-il-9 antibody formulations and uses thereof
RU2010150093A (en) COMPOSITIONS OF PEPTIDES AND METHODS FOR PRODUCING THEM
EP2497484A3 (en) A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
RU2016124562A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF METABOLIC SYNDROME
CA2596966A1 (en) Implantable osmotic device for continuous delivery of suspension formulations
WO2009009727A3 (en) Ghrh analogs and therapeutic uses thereof
KR20190025824A (en) Nicotine particles and compositions
WO2012115208A1 (en) Glp-1 analogue composition for microneedle devices
Flatt et al. Recent advances in antidiabetic drug therapies targeting the enteroinsular axis
KR20110093812A (en) Aqueous composition containing follicle-stimulating hormone
US20200129424A1 (en) Microneedle system for applying glucagon-like peptide analogues
KR101699677B1 (en) Formulation for gonadotropins
EP2258368A3 (en) Pharmaceutical compositions for nasal delivery
US20060198894A1 (en) Stabilized, solid-state polypeptide particles
EP3225235B1 (en) Stable peptide formulations for parenteral injection
WO2019193353A1 (en) Medical infusion pump system for the delivery of an insulin compound

Legal Events

Date Code Title Description
EEER Examination request